Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III single-blind randomized trial of insulin lispro Mix 50 (50R) in type 2 diabetes
CTR20180420Phase 3Completed
- Sponsor
- Wanbang Biopharmaceuticals
- Start
- May 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of insulin lispro + insulin lispro protamine in type 2 diabetes mellitus (T2DM), sponsored by Wanbang Biopharmaceuticals. Started May 2018; status: completed.
02
Drugs
insulin lispro + insulin lispro protamine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20180420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180420.